еНаука - преглед

Преглед према Аутор Dyagil, Irina

Приказ резултата 1 до 2 од 2
ГодинаНасловАутор(и)Тип резултатаМп-кат.
2007Multicenter, randomized, phase III study comparing imatinib (Glivec) standard dose (400 mg/d) with imatinib high dose induction (800 mg/d) followed by imatinib maintenance (400 mg/d) in patients with pretreated Ph+/BCR-ABL(+) CML in chronic phase - ResultPetzer, Andreas L; Wolf, Dominik; Fong, Dominic; Lion, Thomas; Dyagil, Irina; Masliak, Zvenyslava; Boskovic, Darinka V; Griskevicius, Laimonas; Lejniece, Sandra; Spasov, Emil;
Gercheva, Liana; Stojanovic, Aleksandar; Peytchev, Dontcho; Tzvetkov, Nikolay; Griniute, Rasa; Stanchev, Atanas; Kwakkelstein, Martin; Ulmer, Hanno; Gastl, Guenther A;
Конференцијски рад
Мп категорија ће бити приказана накнадно.
2011Pre-treated CML Patients in chronic phase (CP) not achieving at least a major cytogenetic remission (MCyR) after imatinib high dose (HD) induction (800 mg/day, 6 months) are at high risk of progression after dose reduction - Sub-analyses from the CELSG phPetzer, Andreas L; Fong, Dominic; Lion, Thomas; Dyagil, Irina; Masliak, Zvenyslava; Bogdanovic, Andrija D  ; Griskevicius, Laimonas; Lejniece, Sandra; Goranov, Stefan; Gercheva, Liana;
Stojanovic, Aleksandar; Peytchev, Dontcho; Tzvetkov, Nikolay; Griniute, Rasa; Oucheva, Radka; Grubinger, T; Kwakkelstein, Marthin; Rancati, Francesca; Gastl, Guenther A; Wolf, Dominik;
Конференцијски рад
Мп категорија ће бити приказана накнадно.